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English, human-only abstracts from January 1, 1992 to December 31. RESULTS: 
Quality of life evaluations for the following compounds were included in the 
review: abiraterone, cabazitaxel, docetaxel, enzalutamide, mitoxantrone, 
radium-223, samarium-153, and strontium-89. Significantly greater quality of life 
response was observed in the enzalutamide population compared to placebo 
(43% vs. 18%) while docetaxel showed significant difference in a head-to-head 
comparison with mitoxantrone on pain response (31-35% vs. 22%) as measured 
by the McGill questionnaire. Cabazitaxel did not show a significant difference in 
pain response compared to mitoxantrone. Abiraterone showed significant 
difference in multiple outcomes: pain palliation (44% vs. 27%) as measured by 
BPI-SF; reduction in fatigue intensity (58% vs. 40%) as measured by BFI; and time 
to HRQoL degradation (12.7 vs. 8.3 months) as measured by FACT-P. Abiraterone 
is the only agent reviewed to be effective in survival, pain palliation and 
progression and HRQoL. Additionally, abiraterone uniquely measured and 
showed benefit in fatigue. No patient-reported outcomes were pursued for 
sipuleucel-T. EORTC QLQ-C30 and FACT-P were the most common HRQoL 
instruments used. CONCLUSIONS: Studies in mCRPC typically include endpoints 
for pain palliation and quality of life improvement. Additionally, novel therapies 
are focusing on pain associated with bone metastases. There is no standard 
HRQoL or pain instrument being consistently used across prostate cancer trials.  
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PATIENT-REPORTED OUTCOMES (PROS) CLAIMS IN PRODUCTS INDICATED FOR 
TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA AND APPROVED IN 
EUROPE AND IN THE UNITED STATES  
Caron M, Emery MP, Acquadro C, Excanez-Virieux MP 
MAPI Research Trust, Lyon, France  
OBJECTIVES: 1) To identify products indicated for treatment of non-small-cell 
lung carcinoma (NSCLC) approved with a PRO labeling claim in Europe and the 
US; and (2) to list the differences found in Europe versus the US in terms of 
products and labeling. METHODS: The search was performed on the Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) approved 
medicinal product labels and on the FDA medical reviews and EMA scientific 
discussions. RESULTS: A total of 15 products (generics excluded) were identified, 
six at the EMA and nine at the FDA. The six products approved by the EMA were 
also approved by the FDA. Four products with a PRO claim were identified in 
Europe (i.e., docetaxel, erlotinib, gefitinib and paclitaxel), and two in the US (i.e., 
paclitaxel and gemcitabine). Most of the PROs identified in the claims were 
quality of life and symptoms. For four products (i.e., docetaxel, erlotinib, gefitinib 
and paclitaxel), the EMA and FDA showed disagreement in terms of PRO labeling. 
The EMA gave a PRO claim (quality of life and symptom) to three products, but 
not the FDA; for paclitaxel, the FDA did not include quality of life in the label. 
Except for gefitinib, the reviews of both agencies were conducted on the same 
clinical studies. The analysis of the medical reviews and scientific discussions 
showed that FDA did not include the PROs in the label because of concerns about 
the quality of the study design, of the analyses, or the questionnaires’ content 
validity. CONCLUSIONS: Our review showed that the patients’ perspective in the 
treatment of non-small-cell lung carcinoma is important for the EMA and FDA. 
However, differences exist in the evaluation of PRO data for inclusion in the 
label. Our analysis suggests a higher receptivity of EMA to quality of life as a 
global concept.  
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PATIENT REPORTED OUTCOMES IN CHRONIC MYELOID LEUKEMIA: A 
SYSTEMATIC REVIEW  
Aggarwal S, Segal J, Messenger M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show 
improvements in health-related quality of life (HRQoL). Chronic myeloid 
leukemia (CML) is now a chronic disease in which HRQoL is becoming important. 
The objective of this study was to review, analyze, and understand trends in the 
PRO instruments used in patients with CML. METHODS: A systematic literature 
search for CML randomized controlled trials (RCTs) with PROs endpoints was 
undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and 
Cochrane. Data was collected for the study size, interventions, year, PRO 
instrument, and results for PROs. Analysis was conducted to identify trends in 
commonly used PRO instruments and results were categorized as positive, 
neutral, or negative. RESULTS: Eight RCTs with a total of 3342 patients were 
identified. In these studies, there were eight different PROs instruments 
identified: FACT-Leu, SF-36, FSI, PSQI, MSAS-SF, FACT-BRM, EQ-5D, and MDASI-
CML. The most commonly used instruments were FACT-Leu (used in 1336 
patients) and FACT-BRM (used in 1199 patients). Five studies reported positive 
results with improvement in quality of life (QoL) symptoms versus comparator 
treatments. Two studies reported results highlighting significant deterioration in 
QoL versus patients with no cancer. One study reported QoL in various types of 
CML and showed significant deterioration in patients with chronic phase CML 
versus those with acute and blast phase CML. Studies also identified two QoL 
domains, depression and fatigue, which matter most for patients with CML. 
CONCLUSIONS: Patients with CML have significant deterioration in their QoL. 
PRO instruments such as FACT-Leu and FACT-BRM can aid in generating 
evidence to show which therapies improve patient QoL.  
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ELECTRONIC VERSUS PAPER-BASED DATA COLLECTION TO ASSESS PATIENT-
REPORTED OUTCOMES  
Agarwal P, Tworek C 
West Virginia University School of Pharmacy, Morgantown, WV, USA  
OBJECTIVES: With increasing interest in patient-reported outcomes and 
technological advances, the mode of data collection has shifted focus from 
paper-based self-administered surveys to computerized electronic device-
assisted surveys. The study purpose was to examine differences in quality of 
data collected, via paper-based vs. electronic web-based surveys delivered via an 
iPod among cancer patients in West Virginia. METHODS: Convenience sampling 
was used to recruit participants from the Mary Babb Randolph Cancer Center 
(MBRCC) in Morgantown, WV. Eligible respondents were: adults 18 years and 
above; receiving treatment or scheduled for follow-up at MBRCC following cancer 
diagnosis; fluent in English; and consented to participate. Respondents were 
screened and no information was retained from those who refused or were 
ineligible. The study was approved by West Virginia University Institutional 
Review Board. Electronic web-based data were saved to a secure server in SPSS 
software format. Data from paper-based surveys were collected and manually 
entered into a SPSS database. RESULTS: There were 87 electronic web-based 
survey responses; however, due to technical issues, only 67 had complete data. 
This missing pattern occurred in the first 20 surveys, although electronic survey 
design did not allow skipping questions. Responses for 101 paper-based surveys 
were recorded with no unique missing pattern identified; however, 12 
respondents skipped the income question, resulting in missing demographic 
data. Web-based surveys handled skip patterns better, with more accurate data 
collection; however, respondents reported difficulties in iPod data collection, 
such as small screen size and difficulty using the slide bar. CONCLUSIONS: 
Despite widespread interest and increasing use, electronic handheld data 
collection devices should be used with caution. Technical problems with internet 
connectivity and missing data submission to web-based servers may be 
limitations. Electronic data collection may also be less appropriate for specific 




NOVEL ELECTRONIC PATIENT REPORTED OUTCOMES TOOL FOR PROSTATE 
CANCER PATIENTS  
Aggarwal S, Topaloglu H 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Patient Reported Outcomes (PROs) play an important role in 
evaluating patient quality of life and comparative efficacy of various treatments. 
Another potential use of PROs is for chronic disease management, which can 
provide useful data to physicians and patients. We developed a novel web and 
phone based PROs tool for management of prostate cancer disease. METHODS: 
PRO methods for prostate cancer were reviewed by analyzing published clinical 
studies. KOLs and patient advocacy groups were interviewed to obtain their 
input for design of PRO disease management tool. Recent technologies for 
developing such tools were reviewed by analyzing available electronic PRO tools. 
PROCDIM design was developed based on secondary research and primary 
interviews. RESULTS: PROCDIM was designed to capture patient reported 
outcomes data such as Quality of Life (using five attributes), adverse events (six 
commonly reported AEs), medications and OTC drugs history, PSA antigen score, 
past surgery and radiation therapy, and record of physician appointments. 
Patients could enter data into PROCDIM using web or phone (iphone or andriod) 
based systems. Data from PROCDIM could be emailed by the patient to the 
provider or could be downloaded by tethering a phone to a computer. Pilot data 
was captured by testing PROCDIM with physicians and patient advocacy groups. 
Based on interviews, PROCDIM was rated superior and highly user friendly 
compared to current chronic disease management tools. Patient outcomes data 
would be collected from a planned IRB approved study. CONCLUSIONS: 
PROCDIM is a valuable tool to capture several patients reported outcomes and 
data for chronic disease management. Such tools could be used for collecting 
data for disease management, clinical trial, and observational studies for various 
chronic diseases.  
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PATIENT PREFERENCES: UNDERSTANDING RISK-BENEFIT TRADE-OFFS OF 
GENOMIC TESTING IN CHEMOTHERAPY DECISIONS FOR BREAST CANCER 
PATIENTS  
Marshall D1, Bombard Y2, Trudeau M3, Leighl N4, Pykerman K5, Deal K6 
1Alberta Bone & Joint Health Institute, Faculty of Medicine, University of Calgary and Principal 
Consultant, Optuminsight, Calgary, AB, Canada, 2Yale University, New Haven, CT, USA, 
3Sunnybrook Health Science Centre, Toronto, ON, Canada, 4Princess Margaret Hospital, Toronto, 
ON, Canada, 5University of Calgary, Calgary, AB, Canada, 6McMaster University, Hamilton, ON, 
Canada  
OBJECTIVES: Gene expression profiling (GEP) of tumours informs baseline risk 
prediction, potentially affecting decisions about adjuvant chemotherapy for 
women with early breast cancer (BrCa), of whom only 15% will experience a 
recurrence. Limited evidence exists on the clinical utility of GEP in chemotherapy 
treatment decisions. We aimed to measure the value of GEP testing information 
in chemotherapy treatment decisions based on risk-benefit tradeoffs from a 
stated preferences study. METHODS: Based on literature review, focus groups 
and interviews with BrCa patients and medical oncologists, we developed a 
discrete choice experiment survey. For our pilot, we surveyed BrCa patients 
(n=27), women from the general public (n=55), and medical oncologists (MOs; 
n=3) across Canada. The DCE included 12 choice tasks with 5 attributes and 3 
scenario profiles considering orthogonality, D-efficiency and level balance. 
Preferences were analyzed using conditional logit and hierarchical Bayes and 
evaluated for goodness-of-fit. RESULTS: Most (>80%) respondents know 
someone who had chemotherapy for cancer. However, few respondents (<10%) 
know someone who had GEP testing. Across the three groups, the most 
important attributes in chemotherapy treatment decisions were (in order): GEP 
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test score indicating likely benefit from chemotherapy, doctor’s estimate of risk 
of cancer returning (based on clinical algorithms), likelihood of permanent side 
effects, trust in cancer treatment doctor, and likelihood of temporary side 
effects. In a scenario of intermediate risk of cancer returning based on clinical 
algorithms alone (no GEP score), 12% of respondents chose chemotherapy 
compared to 89% of respondents with a GEP score of 44 (high likelihood of 
benefit from chemotherapy). CONCLUSIONS: GEP testing is highly valued and 
strongly influences chemotherapy treatment decisions in all three groups. These 
findings provide preliminary evidence supporting the clinical utility of GEP in 
BrCa treatment decisions.  
 
PCN111  
IMPACT OF BONE METASTASES (BM) ON THE HUMANISTIC BURDEN IN 
PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)  
Hechmati G1, Arellano J2, Haynes I3, Worsfold A4, Rider A4 
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Ltd., 
Uxbridge, UK, 4Adelphi Real World, Macclesfield, Cheshire, UK  
OBJECTIVES: Prostate cancer is the most prevalent form of cancer in men and 
the leading cause of cancer death. In the majority of cases, prostate cancer will 
become castration-resistant; a progressive state whereby most patients develop 
BM with an associated impact on quality of life and life expectancy. We 
evaluated the impact of BM on performance status (Karnofsky score) and pain 
indicators (EQ-5D and FACT-P) in patients with CRPC. METHODS: Data were 
extracted from the Adelphi Real World Prostate Cancer Disease-Specific 
Programme©(DSP), a cross-sectional survey of 348 urologists/oncologists and 
their prostate cancer patients, conducted December 2009–May 2010 in France, 
Germany, Italy, Spain and the UK. Each physician completed comprehensive 
record forms on 10 patients receiving treatment for prostate cancer. Patients 
were also invited to complete a questionnaire, which included EQ-5D and FACT-
P tools. RESULTS: Of the 3477 prostate cancer patients included, 1180 (34%) were 
defined as having CRPC with a median time since diagnosis of 35.8 months: 146 
(12%) patients were categorized as being high risk for developing BM (‘high risk’: 
Gleason score ≥8, or, most recent PSA≥8ng/mL, or, PSADT≤6 months, or, received 
local therapy + systemic medication); 680 (58%) patients had BM. Karnofsky 
scores of 85.1 and 75.7 were reported for high risk patients and those with BM, 
respectively (p<0.0001). Symptoms were reported in 60 (41%) and 487 (72%) high 
risk and BM patients, respectively (p<0.0001) and no pain/discomfort (EQ-5D) was 
reported by 19 (51%) vs 38 (23%) patients (p=0.0009), respectively. Eleven (41%) 
high risk patients and 21 (14%) patients with BM stated no impact of pain on 
daily activities (FACT-P) (p=0.0026). CONCLUSIONS: Developing BM impacts 
patient performance status and pain burden. There is a need for treatments to 




USE OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-ANEMIA  
(FACT-AN) INSTRUMENT IN PERSONS WITH MPN-ASSOCIATED 
MYELOFIBROSIS AND ANEMIA  
Hudgens S1, Gale RP2, Tencer T2, Khan Z2 
1Adelphi Values, Boston, MA, USA, 2Celgene Corporation, Summit, NJ, USA  
OBJECTIVES: Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a 
cancer in which anemia is common. The Functional Assessment of Cancer 
Therapy (FACT) –Anemia instrument measures general quality of life (QOL) and 
anemia-related concerns of people with cancer. We assessed the relationship 
between anemia response to therapy with pomalidomide and domains of the 
FACT-An instrument. METHODS: Data were from a phase-2 randomized double-
blind Bayesian “pick-the-winner” trial of pomalidomide and prednisone in 
subjects with MPN-associated myelofibrosis and anemia (including RBC-
transfusion-dependence). Details of the study, including definitions of anemia 
response, RBC-transfusion-dependence and –independence are reported. Change 
in QOL from randomization to the last cycle of therapy was evaluated using the 
FACT-An physical well-being (PWB), functional well-being (FWB), trial outcome 
index (TOI) and anemia (An) domains. Minimally clinically important differences 
(MID) were used to determine the smallest difference in scores which subjects 
perceived as beneficial in the FACT-An domains of interest. Subjects were 
classified as meeting MID for responsiveness if their change score from baseline 
was greater than one standard error of measurement (SEM) indicating 
improvement. RESULTS: Eighty-five subjects were studied. All FACT-An domains 
showed strong reliability as measured by Cronbach alpha (PWB α=0.77, FWB 
α=0.87, An α=0.92, TOI α=0.95). Thirty-one subjects were classified as anemia 
responders by clinical and laboratory criteria. Anemia responders showed 
greater improvement in PWB, FWB and TOI scores than non-responders across 
all FACT-An domains. Improvement began at the second 28 day cycle of therapy 
and was sustained. CONCLUSIONS: We show anemia response correlates with 
improved QOL measured by the FACT-An instrument in persons with MPN-
associated myelofibrosis receiving pomalidomide.  
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ASSESSING THE IMPACT OF PATIENT-REPORTED OUTCOMES AND HEALTH 
ECONOMIC BENEFIT CLAIMS ON THE MARKET VALUE OF ONCOLOGIC 
PHARMACEUTICALS  
Miller JD1, Ruiz KM1, Gagnon DD2, Foley KA1, Varker HV1, Lenhart GM1 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Santa Barbara, CA, 
USA  
OBJECTIVES: To evaluate the impact that patient-reported outcomes (PRO) and 
health economic (HE) benefit claims made in product labels and in published 
literature have on market value of oncologic pharmaceuticals in the US. 
METHODS: A target list of 13 advanced/metastatic cancers and 32 drugs with 
labeled indications for them were combined into 37 unique “drug-indication 
pairs.” Drugs were antineoplastic agents with FDA approval ≤ 2009. PRO claims in 
US and EMA labels were identified through a commercial research database. PRO 
and HE claims made in published literature were identified through review of 
abstracts published 2000-2010. Economic data (i.e., market size and market share 
in 2010) for drug-indication pairs were extracted from MarketScan® claims 
databases. Data were compiled into an analytic file and one primary and four 
secondary regression models were specified, adjusting for relative drug safety 
and efficacy. The dependant variable in each model represented dollar-value 
market share in 2010 of each drug in its cancer indication. RESULTS: Results 
indicate that PRO claims in US product labels are associated with positive 
increases in market value of oncologic pharmaceuticals. Presence of a label PRO 
claim was associated with 66% increase in market share—about the same 
economic impact conferred by superior drug efficacy. Results were not 
statistically significant in the model for US labels alone (p<0.18), but were 
significant when combining US and EMA labels (p<0.03). No significant 
association was found between PRO and HE claims made in published literature 
and market value of oncologic pharmaceuticals. CONCLUSIONS: Our analysis 
fills gaps in understanding the economic value of PRO and HE benefit claims for 
oncologic pharmaceuticals and sets precedence for undertaking similar studies 
in oncology and other disease areas. Results reinforce that industry should 
carefully evaluate potential positive returns for investing in inclusion of PRO and 
HE endpoints in clinical trials.  
 
PCN115  
PHASE IB STUDY OF PATIENTS RECEIVING TOPOTECAN BY CONVECTION-
ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS: 
NEUROCOGNITIVE FUNCTIONING AND QUALITY OF LIFE OUTCOMES  
Oberg JA, Dave A, Bruce JN, Sands SA 
Columbia University, New York, NY, USA  
OBJECTIVES: Malignant gliomas are highly proliferative, invasive tumors that are 
resistant to conventional treatment and are typically accompanied by 
progressive physical and mental debilitation. We evaluated neurocognitive 
functioning (NCF) and quality of life (QOL) as part of a prospective Phase Ib dose-
escalation study of topotecan by CED in patients with recurrent gliomas. 
METHODS: Secondary data analysis was conducted on the 16 patients enrolled 
on the Phase Ib study. Independent-sample t-tests were used to explore 
differences. Patients received serial assessments at baseline, 1-, 2-, 3-, and 4-
months post-treatment. NCF and QOL were assessed using the HeadMinder 
Cognitive Stability Index and the SF-36, respectively. RESULTS: Patients were 
predominantly male (68.7%) with a median age of 50 years (Range=22-71 years). 
Tumor volume and total infused dose of topotecan were not associated with any 
of the outcome variables. NCF was better for early responders (ERs) than patients 
with progressive disease (PD) or pseudoprogression (PP). Processing speed for ERs 
(n=4) averaged over the follow-up period was significantly higher (z=1.95 SD) 
than patients with PD (n=5; z=-0.61 SD) (p=0.006). Similarly, change in response 
time was better for ERs compared to those with PD (z=4.40 SD; z=-0.52, 
respectively; p=0.04). At baseline, SF-36 results for physical and mental QOL were 
within normal limits. Relative to baseline, average change in SF-36 scores post-
treatment suggest that overall mental QOL was significantly higher for ERs (MCS 
change score=5.04) than patients with PD (MCS change score=-6.48) (p=0.02), 
reflecting better emotional well-being. Average change in physical QOL was not 
significantly different between ERs, PD or PP. CONCLUSIONS: These results 
provide the beginning framework to better understand NCF/QOL outcomes in 
patients with recurrent malignant gliomas treated with topotecan by CED. 
Continued monitoring of these outcomes will be important in the phase II trial to 
assess treatment efficacy and impact on NCF and QOL.  
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ESTIMATION OF POTENTIAL GAIN IN QUALITY OF LIFE FROM EARLY 
DETECTION OF CERVICAL CANCER  
Hung MC1, Wang JD2 
1Department of Public Health, National Cheng Kung University Medical College, Tainan, Taiwan, 
2National Cheng Kung University College of Medicine, Tainan, Taiwan  
OBJECTIVES: To compare dynamic changes of the health-related quality of life 
(HRQL) in patients with invasive cervical cancer and carcinoma in situ for 
estimation of potential gain in quality of life from early detection. METHODS: All 
patients diagnosed with cervical cancer who visited the cancer clinic at the 
National Cheng Kung University Hospital from March 2012 to September 2012 
were invited to participate in the study. They were classified into 4 groups 
according to treatment modalities: Carcinoma in situ post conization, invasive 
cancer treated with operation only, those treated with operation plus 
chemotherapy or radiotherapy, and those treated with chemotherapy or 
radiotherapy only. The WHOQOL-BREF (World Health Organization Quality of 
Life – brief version) questionnaire was used to measure the HRQL. The dynamic 
changes of HRQL scores were calculated with the kernel smoothing method.  
A mixed-effect model was constructed to analyze repeated measurements and 
determine risk factors for impairment of HRQL and different treatment 
modalities. RESULTS: A total of 507 measurements were collected from 421 
patients. In comparison with carcinoma-in-situ patients post conization, 
patients with invasive cervical cancer who received operation plus 
chemotherapy or radiotherapy showed consistently lower scores in facets  
of physical and psychological domains and sexual activities after adjustment for 
age, education, marital status, co-morbidities and duration after diagnosis.  
The differences in scores seemed to be reduced temporarily 4-8 years after 
diagnosis. CONCLUSIONS: Early detection of cervical cancer may avoid 
impairment of quality of life in physical, psychological domains, and sexual 
activities.  
